v3.10.0.1
Consolidated Balance Sheets - USD ($)
Sep. 30, 2018
Dec. 31, 2017
Current Assets    
Cash and cash equivalents $ 20,962,319 $ 9,763,067
Accounts receivable 68,238 14,833
Prepaid expenses and other current assets 2,477,751 1,967,257
Total Current Assets 23,508,308 11,745,157
Property and Equipment, net 663,065 286,891
Other Assets    
Restricted cash 2,292
In-process R&D 5,866,000 5,866,000
Goodwill 2,189,338 2,189,338
Deposits 99,220 69,798
Deferred financing costs 30,000
Total Other Assets 8,154,558 8,157,428
Total Assets 32,325,931 20,189,476
Current Liabilities    
Accounts payable 976,090 1,033,680
Deferred revenue 3,090,675 6,826,388
Contingent consideration 1,217,000  
Accrued expenses and other liabilities 1,530,820 2,276,431
Total Current Liabilities 6,814,585 10,136,499
Long Term Liabilities    
Other long term liabilities 188,482 160,559
Deferred tax liability 637,140 1,302,220
Deferred revenue, net of current portion 200,000 200,000
Contingent consideration, net of current portion 2,058,225 2,609,289
Total Liabilities 9,898,432 14,408,567
Commitments and Contingencies
Stockholders' Equity    
Common stock, $.0002 par value; 100,000,000 shares authorized, 23,235,596 and 4,200,310 shares issued and outstanding at September 30, 2018 - unaudited) and December 31, 2017, respectively 4,647 840
Additional paid-in capital 104,378,324 76,382,262
Accumulated deficit (79,642,034) (68,846,326)
Accumulated other comprehensive loss (55,377) (166,025)
Total Stockholders' Equity-Heat Biologics, Inc. 24,685,560 7,370,751
Non-Controlling Interest (2,258,061) (1,589,842)
Total Stockholders' Equity 22,427,499 5,780,909
Total Liabilities and Stockholders' Equity $ 32,325,931 $ 20,189,476

Source